Podcasts about dupixent

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent weeks have been a whirlwind of activity in the pharmaceutical and biotech sectors, showcasing significant strides in scientific breakthroughs, regulatory advancements, and strategic industry maneuvers. Replimune's Vusolimogene Oderparepvec has emerged as a beacon of hope in the fight against advanced melanoma. This gene therapy, utilizing an oncolytic virus, has recently received a positive nod from an advisory committee for its Phase 1/2 trial. When combined with PD-1 checkpoint inhibitors, it holds promise for enhancing immune responses against tumors—a critical development in cancer treatment that may redefine therapeutic strategies. This advancement follows two prior FDA rejections, underscoring the multifaceted evaluation process drugs undergo before approval and demonstrating that perseverance can eventually lead to success. Meanwhile, AstraZeneca and Daiichi Sankyo have achieved a milestone with the European Union's approval of Datopotamab Deruxtecan for treating unresectable or metastatic triple-negative breast cancer (TNBC). As an antibody-drug conjugate targeting the Trop-2 protein, it offers new hope to TNBC patients who often have limited options. This approval underscores the potential of antibody-drug conjugates in oncology, supported by promising Phase 3 trial data. Regeneron Pharmaceuticals is enjoying notable revenue growth thanks to Dupixent, a monoclonal antibody addressing autoimmune and respiratory diseases. Such financial success underscores the expanding role of biologics in tackling chronic illnesses, reflecting a broader industry trend towards biologically-based treatments. In business news, Pharmanovia's licensing deal with Impact Therapeutics for Senaparib signifies strategic expansion in oncology therapeutics. Similarly, Kaigene's agreement with Taisho Pharmaceutical highlights ongoing interest in autoimmune therapies, illustrating how companies are leveraging partnerships to broaden their therapeutic horizons. Pfizer is on the brink of expanding its label for Ritlecitinib (Litfulo), a JAK3 inhibitor that showed positive results in Phase 3 trials for nonsegmental vitiligo. By targeting autoimmune pathways, this small molecule could offer new hope to vitiligo patients seeking effective treatments. Litfulo is advancing through regulatory stages following successful trials, poised to provide an oral alternative for non-segmental vitiligo—a potential game-changer that could improve patient compliance and expand treatment options beyond Incyte's Opzelura. However, not all news is positive. Novo Nordisk faced disappointment when its Ziltivekimab failed a Phase 3 trial for atherosclerotic cardiovascular disease with chronic kidney disease. Despite this setback, Novo Nordisk remains optimistic about ongoing trials Artemis and Hermes as potential lifelines for their CKD program. Success could diversify their portfolio and introduce novel therapeutic options for CKD patients. Additionally, financial hurdles surfaced as Daiichi Sankyo saw an 11% share drop due to an accounting error, and Alnylam Pharmaceuticals' market value took a hit following a lowered revenue forecast for its TTR drug. On a global scale, the Trump administration has allocated $600 million to GAVI for childhood immunizations worldwide. This funding reversal emphasizes ongoing efforts to ensure vaccine accessibility across the globe—an essential component of public health initiatives. The dynamic nature of these developments reflects both the potential and challenges within the pharmaceutical landscape. The promising avenues presented by gene therapy, antibody-drug conjugates, and JAK inhibitors are tempered by clinical setbacks and financial volatility, underscoring the rigorous demands faced by industry stakeholders. In other industry news, AbbVie's Skyrizi continues to thrive despite increasing competition in the psoriasis market. With sales reaching $5.55 billion in Q2 2026, Skyrizi demonstrates the sustained demand for innovative biologics that enhance treatment efficacy and safety profiles. Karyopharm Therapeutics remains committed to its XPO1 inhibitor Xpovio despite setbacks in other indications like endometrial cancer. Their focus on myelofibrosis illustrates a strategic pivot towards hematologic malignancies where unmet needs persist. Oral GLP-1 receptor agonists are gaining ground as Novo Nordisk's Wegovy pill and Eli Lilly's Foundayo vie for dominance in weight management solutions. These oral formulations promise increased accessibility over traditional injectables. Regulatory arenas continue to evolve with AbbVie's Rinvoq gaining European clearance for alopecia and vitiligo. Such approvals highlight regulatory bodies' critical role in expanding market access across diverse therapeutic areas. Strategic partnerships also abound as WellSpan Health collaborates with Hippocratic AI to integrate artificial intelligence into healthcare solutions—a growing trend aimed at enhancing clinical decision-making capabilities. Meanwhile, Apnimed's $192 million IPO success indicates strong investor confidence in novel therapeutics like its sleep apnea treatment—a reflection of biopharma's financing dynamics where targeted therapies draw significant interest. Overall, these updates paint a vivid picture of an industry characterized by relentless innovation through scientific research, strategic alliances, and regulatory progress—all aimed at improving patient outcomes amidst evolving market demands. The industry's focus on breakthrough technologies continues to shape global health initiatives by offering new opportunities for patient care across various conditions. As companies navigate this dynamic environment marked by both promise and challenge—their ability to innovate scientifically while engaging strategically with regulators will be crucial to bringing novel therapies effectively into clinical practice where they can make meaningful impacts on patients' lives worldwide.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of events that underscore the dynamic nature of these industries, characterized by scientific advancements, strategic partnerships, and regulatory milestones. Johnson & Johnson has made headlines with its substantial $785 million upfront payment to Sail BioMed for an in vivo CAR-T cell therapy deal. This agreement includes an option for Johnson & Johnson to acquire Sail BioMed for $2.58 billion, underscoring the sustained interest in cell therapies, particularly for autoimmune diseases. In vivo CAR-T therapies represent a significant leap forward by modifying T cells directly within the patient's body. This method offers potential advantages over traditional ex vivo techniques by simplifying the manufacturing process and potentially reducing both costs and time to treatment. Such transactions highlight Johnson & Johnson's commitment to expanding its cell therapy portfolio, which could significantly enhance patient care by making advanced treatments more accessible. Eli Lilly and Resilience have announced a significant $750 million investment aimed at boosting the production of diabetes and obesity medications in the United States. This move comes as a response to the global rise in these conditions, necessitating increased production capacities to meet growing demand. The focus on injectable drug devices emphasizes efforts to improve drug delivery systems, ultimately enhancing patient compliance and therapeutic outcomes. Sanofi's financial outlook for 2026 is promising, driven by robust sales of Dupixent, which exceeded €5 billion in quarterly sales. Dupixent, a monoclonal antibody used for treating atopic dermatitis and other autoimmune conditions, has been a significant revenue driver for Sanofi. The success of Dupixent reflects its effectiveness and strong market adoption, highlighting the potential of monoclonal antibodies as cornerstones of modern pharmacotherapy, particularly for chronic inflammatory diseases. Regeneron and Sanofi's Dupixent continues performing strongly with $6 billion in sales during Q2 2026—marking its largest quarterly revenue since the pandemic began—illustrating robust demand across various indications within both companies' portfolios. On the regulatory front, Alfasigma's Linerixibat (Lynavoy) has received a positive opinion from the CHMP for treating cholestatic pruritus in primary biliary cholangitis following successful Phase 3 trials. As an IBAT inhibitor targeting bile acid metabolism pathways, Lynavoy introduces a novel therapeutic approach for managing symptoms associated with this autoimmune liver disease. Meanwhile, ImmunityBio's Anktiva has gained marketing authorization in the UAE for non-muscle invasive bladder cancer and metastatic non-small cell lung cancer. Anktiva, an IL-15 cytokine-based protein therapy, exemplifies the growing interest in harnessing immune system modulators for cancer treatment. Takeda's recent decision to discontinue its nanoparticle therapy (TAK-101) for celiac disease highlights the inherent challenges in developing new therapies for autoimmune disorders. The disappointing Phase 2 results suggest that achieving immune tolerance to dietary gluten remains a significant scientific hurdle. From a strategic perspective, Sanofi's CEO has emphasized stricter go/no-go decisions during Phase 3 clinical trials amid pipeline cuts and significant impairment losses. This approach could lead to more efficient resource allocation and potentially higher success rates for late-stage drug candidates. The industry is witnessing significant transformations through strategic shifts driven by executives like Sanofi's new CEO Belen Garijo. Her vision includes reversing recent challenges faced by Sanofi by capitalizing on its strengths while addressing setbacks such as discontinuing certain late-stage clinical programs like the joint venture with Regeneron on the IL-33 candidate itepekimab. This strategic pivot mirrors broader industry trends toward optimizing late-stage pipelines to enhance competitive positioning and drive future growth. Advancements in AI-powered drug discovery continue gaining momentum through collaborations like those between GSK and Relation Therapeutics, alongside Causaly and Sage. These partnerships aim to leverage AI and machine learning technologies to accelerate drug discovery processes by integrating vast amounts of scientific literature into data analytics platforms. GlaxoSmithKline's $110 million deal with an AI biotech firm further signals increased integration between artificial intelligence technologies and pharmaceutical research efforts aimed at enhancing dataset quality thereby accelerating innovation throughout drug discovery processes. Bristol Myers Squibb faces further delays regarding its Alzheimer's psychosis treatment Cobenfy—a postponement reflecting ongoing complexities related to neurological drug development which requires overcoming high scientific hurdles alongside regulatory scrutiny. Alnylam Pharmaceuticals recently experienced a 29% drop in stock value following disappointing sales of Amvuttra and a downward revision of its ATTR franchise outlook for 2026. Such fluctuations highlight volatility within biotech investments when market expectations are not met. These collective developments reveal significant trends shaping today's pharmaceutical landscape: strategic pipeline optimization efforts alongside robust investment initiatives targeting high-demand therapeutic areas—all while leveraging technological advancements like AI integration aimed at improving R&D efficiency ultimately impacting patient care worldwide through innovative therapies addressing unmet medical needs globally.Support the show

Bonjour Léo,L'indice parisien a été porté par une salve de résultats, bien accueilli dans l'ensemble par les investisseurs et termine proche de +1% sa séance.Schneider Electric s'est envolé de près de 11% après avoir dévoilé un chiffre d'affaires record au premier semestre.Il s'établit à 21.2 Milliards d'euros, soit une croissance organique de 14%.Bouygues grimpait de près de 7% après avoir dévoilé un chiffre semestriel à 26.3 milliards d'euros, légèrement supérieur aux attentes du consensus.Le groupe de construction et de télécommunications a confirmé ses perspectives pour l'ensemble de l'année 2026 et vise un chiffre d'affaires stable à taux de changes constants.En revanche, déception sur d'autres sociétésLa société pharmaceutique Sanofi a perdu près de 9%, malgré de bons résultats trimestriels.Les investisseurs se sont focalisés notamment sur la dépendance du groupe à leur médicament phare, le Dupixent, qui représente 42% des ventes.Le marché s'inquiète du coût des acquisitions qui se profilent pour le remplacer d'ici à 2031, quand son brevet tombera.Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.

It's easy to blame yourself when medications like Dupixent, Adbry, or Ebglyss don't work (or work well enough), your doctor says that you've “failed” it and it's time to move on to something else. Very often, no one is asking, "Why wasn't Dupixent able to work in the first place?" which could uncover important clues about your eczema case potentially lurking under the surface.Because YOU didn't fail the drug, and before moving on to something else, this is what you absolutely need to consider.Plus, we'll talk about a little-known warning in the safety information for Dupixent and other IL-13-blocking biologics specifically about parasites. So let's dive into what I've seen in clients prescribed these medications and why what looks like drug failure to their doctor could be an important root cause clue.⭐️Mentioned in This Episode:- See all the references

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we explore the latest advancements shaping the future of drug discovery and patient care. Veradermics is making significant strides with its oral minoxidil formulation aimed at addressing female pattern hair loss. The mid-stage clinical trial results have analysts optimistic about Veradermics' potential to capture a significant portion of this underserved market. The oral form of minoxidil, traditionally used in topical Rogaine products, offers a novel delivery method that could enhance patient adherence and improve outcomes, marking an innovative leap in dermatological treatments. Johnson & Johnson is navigating the expiration of Stelara's patent protection with resilience, as Tremfya steps up to fill the revenue gap. With quarterly sales exceeding $2 billion, Tremfya underscores the critical role of strategic lifecycle management and robust product pipelines in weathering patent cliffs. This success highlights the necessity for pharmaceutical companies to sustain growth through a well-rounded portfolio that can absorb such impacts. In oncology, Celcuity has achieved a pivotal milestone with FDA approval for its small molecule inhibitor targeting breast cancer. This therapy promises blockbuster potential and could become a new standard-of-care, expanding treatment options for patients. The approval reflects ongoing innovation in oncology, where small molecules continue to play an essential role alongside biologics in advancing cancer therapies. AI-driven drug discovery is gaining traction as Insilico Medicine partners with CDMO Bora in a potentially $2.5 billion deal. This collaboration underscores AI's transformative potential in accelerating drug discovery and development processes. By leveraging artificial intelligence, Insilico aims to identify new drug candidates more efficiently, expediting their journey from bench to bedside. Kelun-Biotech is marking significant progress with its SAC-TMT program targeting non-small cell lung cancer (NSCLC), filling gaps left by Merck's phase 3 efforts. This development is crucial for providing more tailored therapeutic options in oncology, illustrating how advancements in drug development are driving forward personalized medicine. Roche continues its exploration of Alzheimer's disease treatments with a multifaceted approach that includes both amyloid and tau proteins as targets. While its phase 3 amyloid program is prominent, Roche's interest in tau protein highlights the complexity of tackling neurological disorders and the need for diverse therapeutic strategies. Meanwhile, Biogen remains steadfast in defending its anti-tau Alzheimer's candidate following mixed phase 2 results that showed slowed cognitive decline. Despite stock volatility, this endeavor illustrates the high-stakes nature of Alzheimer's research as companies pursue novel approaches to this challenging disease. Regulatory landscapes are also shifting as Johnson & Johnson halts development of an eye disease gene therapy after disappointing phase 2b results. This move reflects the inherent risks involved in gene therapy and underscores the necessity for thorough evaluation at each clinical stage. Medtronic's recall of its Harmony delivery catheter system due to potential detachment risks serves as a reminder of the paramount importance of safety and quality control in medical device manufacturing. Such recalls impact patient safety and emphasize regulatory vigilance over device reliability. In summary, these innovations demonstrate the dynamic nature of the pharma and biotech industries where cutting-edge science drives progress. Integrating AI into drug discovery, managing product lifecycles post-patent expiry, advancing personalized medicine, and maintaining regulatory diligence collectively shape a landscape focused on improving patient outcomes worldwide. Turning to recent scientific developments: Eli Lilly's presentation at AAIC 2026 on their anti-amyloid Alzheimer's drug Kisunla explores maintenance therapy possibilities once amyloid levels fall below a threshold. This potential shift could signify a paradigm change by extending therapeutic benefits and possibly improving long-term outcomes for patients with Alzheimer's. Biogen's advances with its anti-tau Alzheimer's therapy partnered with Ionis Pharmaceuticals further validate the tau hypothesis. The promising mid-stage data on their antisense drug Diranersen opens opportunities for other companies like Denali Therapeutics to explore similar avenues for treating neurodegenerative diseases. The industry is also witnessing a resurgence in biotech IPOs during 2026's first half, recovering from a sluggish 2025. This surge signals investor confidence in biotechnological innovation while providing capital for advancing research pipelines. Financial activities within the sector are robust as Attovia Therapeutics files for an IPO to fund its competitive pipeline against Sanofi's Dupixent. Meanwhile, Advancell's $315 million Series D funding supports advancing prostate cancer candidates into Phase 3 trials, backed by big pharma confidence in radiotherapy's potential. Lastly, regulatory transparency improves as the FDA resumes releasing drug rejection letters after a temporary pause—a move likely to influence future submissions significantly by offering clearer guidance on regulatory expectations. These developments collectively highlight how scientific innovation and strategic maneuvers transform pharmaceutical landscapes, promising profound impacts on patient care through advanced therapies and novel treatments worldwide. As these trends unfold, they reflect an industry increasingly reliant on technological integration and collaborations to drive future growth and innovation.Support the show

When sunny summer days come around, it makes some dermatologists shudder. They would prefer we behave like bats and hide in caves until nightfall. Failing that, they stress the importance of always applying (and re-applying) high SPF sunscreen, wearing sun-blocking clothing with long sleeves and keeping a big-brimmed hat firmly on the head. A beekeeper's outfit might be perfect. But must you really shun the sun completely to save your skin? Our guest describes how to practice moderation safely. He also explains why some people are addicted to sunshine, while others are allergic to it. At The People's Pharmacy, we strive to bring you up to date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, July 11, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on July 13, 2026. Can You Really Be Addicted to Sunlight? Dermatologists do their best to discourage people from using tanning beds. They describe the damage that ultraviolet light can cause, ranging from wrinkles to skin cancer. For some people, though, those arguments just don't make a difference. Our guest, Dr. Steve Feldman, conducted a study several years ago. The volunteers were accustomed to using tanning beds. In the study, there were two beds, one with the usual ultraviolet light and the other, identical in appearance and temperature, had its UV blocked. After a session in each bed, volunteers were allowed to choose their bed for the last session. They almost invariably chose the bed with the active UV. To follow up, the researchers administered naltrexone, the opioid-blocking medication. When volunteers had taken it, they were no longer able to distinguish which bed was active. It seems that, for these people, ultraviolet light activates pro-opiomelanocortin, which in turn triggers the production of natural opioids called endorphins. Further research imaging the brain during tanning sessions confirmed that the UV exposure was activating areas of the brain associated with pleasure (Psychiatry Research. Neuroimaging, May 30, 2016).  Dr. Feldman and a colleague found that excessive indoor tanning is similar in pattern to substance use disorders (Journal of Cutaneous Medicine and Surgery, May-June 2025). Can You Save Your Skin and Still Enjoy the Outdoors? Dr. Feldman offers advice on avoiding sunburn that is tempered with this fact from epidemiology: people who go out in the sun live longer (International Journal of Environmental Research and Public Health, July 13, 2020).  The goal here is not to shun the sun completely, but rather to exercise enough caution and good judgment to avoid burning your skin. (Who wants to burn, anyway? It hurts, and it looks bad.) Timing your sun exposure carefully is crucial to save your skin from sunburn. You may also be interested in the new sunscreen ingredient the FDA just approved, bemotrizinol. What Can You Do About Heat Rash? When the weather gets hot and bodies get sweaty, heat rash becomes a common complaint. Sweaty skin may develop bumps that can sometimes be very itchy. What do you do to ease the discomfort? If you can cool the skin off, it might help a lot. Of course, people may also suffer from other types of rash. Babies get diaper rash. Women sometimes experience under-breast rash, just as men may develop jock itch. Zinc oxide ointment can often be helpful for these types of rash. Managing Psoriasis Psoriasis is one of Dr. Feldman's special research interests. The red scaly plaques of this skin condition have raised borders. They look a lot like a fungal infection, but there is no fungus present on the skin to cause them. Something else seems to trigger the skin's immune system to react along the same pathways as if there were a fungus. Most of the time, psoriasis is mild enough to manage without costly medications. It actually responds very well to ultraviolet light exposure. UV downregulates the immune system's over-response. While many dermatologists offer UV exposure within their office walls, in the summertime patients could get exposure to sunlight outdoors. This is practical if they avoid the middle of the day, when they might get burned. Another option? Tanning beds also offer an easy way to calibrate the appropriate amount of UV exposure to save your skin from psoriasis. (Most dermatologists don't approve of this one, so don't tell.) One other practical but unorthodox tip for dealing with mild psoriasis. OTC cortisone may not be strong enough to help heal up a red spot. But you could buy Flonase nasal spray or a generic version, fluticasone, over the counter. Spray it on your skin and appreciate the relief. In fact, this could work for a mild case of poison ivy or other skin irritation as well. Severe cases still need a dermatologist's care. What to Do About Atopic Dermatitis Atopic dermatitis is the medical term for eczema. People with allergies or asthma also appear to be more vulnerable to eczema. Dysregulation of the immune mediators interleukin 4 (IL4) or IL13 may be responsible. This condition may appear in a mild form, which can be readily managed, or a more severe form that might require prescription medication. A topical corticosteroid such as triamcinolone will often clear it up. Or you could try spraying on some Flonase nasal spray for a cost-effective low-key approach. Those will actually help the majority of people with mild eczema. Using mild soap rather than detergent-based body wash, moisturizing well and following an anti-inflammatory diet are the pillars of home management. People with more severe atopic dermatitis covering a large portion of the body may need powerful prescription medication rather than topical steroids. Trying to cover so much skin with steroid would probably result in side effects from the cream. Dupixent (dupilumab) is a relatively new self-injectable medication that blocks IL4 and IL13. It works well for most people with atopic dermatitis and has a good safety profile. Certain other drugs in this category, such as Skyrizi (risankizumab), are also pretty safe but very pricey. Stelara (ustekinumab), has been around longer. Biosimilars for Stelara have been approved and are more affordable. Ustekinumab blocks IL12 and IL23. TV ads tout other medicines for this condition as well. Rinvoq (upadacitinib) is three or four times more effective than Dupixent, but it is also super expensive. It is a Janus-kinase (JAK) inhibitor. Xeljanz (tofacitinib) is another potent prescription JAK inhibitor, but it carries an elevated risk of heart attack. Beware of Bug Bites Another summer skin hazard is bug bites. Here unquestionably the best approach to save your skin is avoidance. Appropriate clothing is key. (That beekeeper's suit will come in handy here again.) Dr. Feldman recommends spraying DEET on your pants legs, socks and sleeves rather than directly on your skin. If there are grasses or brush where you have walked, run or played, a tick check immediately upon coming inside is critical. Can AI Help Patients with Skin Problems? It doesn't make sense to tell people to stay off the internet. Some searches can be quite helpful and guide patients in asking their dermatologist the right questions. Dr. Feldman is enthusiastic about DermNet, a New Zealand dermatology website. https://dermnetnz.org  Joe and Terry recommend SkinSight. This Week’s Guest Steven R. Feldman, MD, PhD, is Professor of Dermatology, Pathology, and Social Sciences & Health Policy, at the Wake Forest University School of Medicine.  His research has been published in over 1,000 peer reviewed, Medline-referenced articles. Expertscape.com ranks Feldman among the top experts in the world on psoriasis, acne, dermatology, and treatment adherence. Steve Feldman, MD, in Dermatology clinic, Country Club Commons Listen to the Podcast The podcast of this program will be available Monday, July 13, 2026, after broadcast on July 11. You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

In this journal club episode, we break down the draft of the Chronic Urticaria Guidelines: 2026 AAAAI/ACAAI Joint Task Force (JTF) on Practice Parameters GRADE- and Institute of Medicine-based recommendations. We explain what counts as chronic hives, why the guideline leans on second-generation non-drowsy antihistamines, what to do when those are not enough, and what is new for both adults and kids. At the time of recording, the draft was open for comments; it closed for comments on June 30, 2026. What we cover in our episode about the new chronic hives guidelines What chronic hives are: A plain-language look at the two main types, spontaneous and inducible, plus angioedema (swelling) that can come with them. What a draft guideline is: Why the guideline is still being reviewed, and how comments can help shape it before it is final. What's new for kids: How children fit into the guideline, and why most do well without advanced treatments. The antihistamine shift: Why the guideline favors non-drowsy, second-generation antihistamines and moves away from older, sedating ones. When antihistamines are not enough: If higher-dose antihistamines do not work, the recommended advanced option is to start omalizumab (Xolair) plus two newer additions: dupilumab (Dupixent) and remibrutinib (Rhapsido). Download Infographic More hive resources  Read the draft guideline and comment details (ACAAI) Track your symptoms: Get the CU Download to access the UAS7 and the Urticaria Control Test (UCT) What are chronic hives? Chronic Urticaria Toolkit Living with Chronic Hives *********** The Itch Review, hosted by Dr. Gupta, Kortney, and Dr. Blaiss, explores allergy and immunology studies, breaking down complex research in conversations accessible to clinicians, patients, and caregivers. Each episode provides key insights from journal articles and includes a one-page infographic in the show notes for easy reference. *********** Made in partnership with The Allergy & Asthma Network. Thanks to Opella for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

This year has been partly defined by a return to M&A. In the first quarter of 2026, biopharma spent nearly $47 billion in acquisitions across 19 deals, and this week, AbbVie notched another one for the second quarter, scooping up Apogee Therapeutics and its IL-23 blocker for atopic dermatitis for around $10.9 billion. The deal follows GSK's $10.6 billion Nuvalent Bio acquisition earlier this month. These deals come as several big pharmas face patent cliffs. Sanofi, for example, will lose patent protection on Dupixent in 2031. New CEO Belén Garijo made a major play to build out Sanofi's pipeline this week, announcing that Xaira veteran Paulo Fontoura will step in as R&D chief as Houman Ashrafian exits.  Another key trend over the past 18 months has been regulatory uncertainty. This trend continues, with both uniQure and REGENXBIO announcing FDA reversals for their gene therapies for Huntington's disease and Hunter syndrome, respectively. Both companies will submit for approval of their products—a first submission for uniQure and a resubmission for REGENXBIO—in the third quarter, after the agency, under the leadership of acting commissioner Kyle Diamantas, deemed their current data sufficient. Also at the FDA, a policy memo on the agency's consideration of Sanofi's Commissioner's Priority Review Voucher for type 1 diabetes drug Tzield threw more fire on the CNPV program, which has already been mired in controversy. And the agency debuted an investigational new drug pilot program that would leverage collaborations with U.S. research institutions to reduce early trial timelines by as much as 12 months. For a special treat, we heard from BioSpace Managing Editor Jef Akst and Senior Editor Annalee Armstrong who are currently in San Diego enjoying BIO 2026. And finally, on the Eli Lilly front, a new report from Evaluate projects that the company's weight loss franchise will account for nearly half of the total sales of the top 10 drugs in 2032. But Lilly isn't resting on this envisioned success: the juggernaut is one of two companies circling Sangamo's assets as the biotech files for bankruptcy.

You may think of allergies as causing sniffly noses and congestion in the spring or fall. But allergies can go far beyond that. As Dr. Kari Nadeau points out in this episode, allergies can affect us from head to toe, including eyes, nose, throat, lungs, sinuses, skin and gut. In the most dangerous instances, the whole body is threatened with an anaphylactic reaction. That's a medical emergency! One in three Americans will develop allergies at some point in our lives, so it's important to know what works to control them. At The People's Pharmacy, we strive to bring you up to date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, June 6, 2026, through your computer or smart phone (wunc.org).  Here is a link so you can find which stations carry our broadcast. (Welcome, Huntsville, Alabama!) If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on June 8, 2026. What Are Allergies? We begin our discussion of your allergy survival guide with an explanation of what is happening during an allergic reaction. The immune system perceives some foreign compound, usually a protein, as dangerous even though normally it would not be. So it reacts by trying to flush the invader out by producing extra mucus. The turbinate sinuses can make one to two gallons of mucus a day, and naturally, it has to go somewhere. That's why you might be congested. Having all that mucus in the sinuses can also encourage bacterial growth, so if the allergic reaction persists, some people have to deal with sinus infections. Emergency Treatment In determining what works, you need to know the nature of the reaction. If you have two or more organs involved, if you are having trouble breathing or if you feel dizzy, you may be in the midst of an anaphylactic reaction. What works for that is an epinephrine injection and immediate medical attention. This is potentially life-threatening, so you will want to figure out what triggered the reaction so you can avoid it in the future. Once someone has suffered one anaphylactic reaction, they should keep epinephrine with them at all times in case of another episode. Epinephrine comes as a self-injector pen or a nasal spray (neffy). Can You Spot Drug Allergies? In the warnings that are rattled off as part of a TV ad for a pricey new drug, we often hear viewers cautioned not to take the medicine if they are allergic to it. That sounds like simple common sense, but it also has a Catch 22 quality. How do you know you are allergic to a medication unless you take it–and experience an allergic reaction for which you might need treatment. Most of these presumably are immune system-mediated reactions, in which the body produces IgE. That is how allergies to penicillin or sulfa drugs work. Some drugs cause a different type of reaction, not IgE-mediated but dangerous nonetheless. Lisinopril is the most commonly prescribed blood pressure medicine in this country. Like other ACE (ACE is short for angiotensin-converting enzyme) inhibitor medications, lisinopril can trigger angioedema. This swelling can affect the face, lips, tongue and throat, where it can compromise breathing. The most insidious aspect of this reaction is that it can occur after the person has been taking the drug without problems for weeks, months or even years. “Red man syndrome” or infusion reactions in people taking vancomycin can likewise occur without warning. The last type of drug reaction is not actually an allergy at all, although people occasionally use that terminology. It is better described as sensitivity. For example, a stomachache is a common reaction to the antibiotic erythromycin. Some people are disabled by this abdominal pain and try to limit their exposure to erythromycin thereafter. What Works and What Doesn't? Since the immune system is acting inappropriately to cause allergic reactions, treatment should involve immunotherapy. Eye drops can help eyes feel less itchy and irritated. Likewise, OTC nose drops or nasal sprays can often help the nose. The corticosteroid Flonase (fluticasone) and the antihistamine Astepro (azelastine) are good examples. During allergy season, some people find that a daily nasal wash (with a neti pot or NeilMed device) can help reduce the mucus and remove the allergens such as pollen causing the reaction. There are also oral antihistamines and inhalers for asthma. For decades now, allergists have offered their patients shots to help desensitize them to the allergen causing their trouble. Joe had these as a child and teenager and has been largely free of allergies since. Not everyone gets such lasting relief. Complications from Current Therapies Medications have side effects, and that is true of allergy medicines as with other drugs. Antihistamines, especially the older ones like Benadryl (diphenhydramine), are notorious for causing drowsiness. That's one reason it is often included in nighttime pain relievers as the “PM” in drugs like Advil PM. We worry about regular use of such antihistamines because it has been linked to a greater risk for dementia. A second-generation antihistamine such as Allegra (fexofenadine) is much less likely to make someone feel sleepy. However, Dr. Nadeau has seen patients on antihistamines suffer worse allergies if they stop suddenly. The People's Pharmacy has received hundreds of reports from people who experienced unbearable itching upon discontinuing Zyrtec (cetirizine) or Xyzal (levocetirizine). This can last for weeks. Doctors don't usually worry much about steroid nasal sprays like Flonase because they are topical. Presumably, nasal tissues pick up most of the dose. Just the same, using such a nose spray day after day for a long time could result in systemic steroid exposure that is not trivial. Stronger Medicine Dr. Nadeau is enthusiastic about the benefits of two potent prescription medicines. One is Xolair (omalizumab). It was originally developed to prevent asthma, but is now approved for chronic sinusitis, food allergies and chronic hives. Paradoxically, Xolair is one of those medicines that could cause a severe allergic reaction even on the first dose, so the FDA warns that the initial injection should be given in a healthcare setting prepared to treat anaphylaxis. This is uncommon, though, occurring in 0.1 to 0.2% of patients. The other medication Dr. Nadeau is prescribing for allergy patients who don't respond well to other treatments is Dupixent (dupilumab). The FDA has approved this medicine to treat a wide range of conditions, including eczema, asthma, chronic sinusitis, allergic reactions affecting the esophagus and chronic hives, among other things. Most insurance companies will not cover this pricey injection unless the patient has failed all other therapies. Fighting Air Pollution: What Works Air pollution makes allergy symptoms worse, so using an effective air filter inside the home is a good step. A HEPA (high-efficiency particulate-arresting) filter is ideal, especially as part of the air-handling system. If that's not possible, utilizing a MERV 13 in the part of the home where you spend the most time is a good second choice. Sonu One new option for treating allergies is acoustic resonance therapy with the SoundHealth Sonu headband. It uses vibration from sound to loosen mucus from the sinuses so that they can clear. The FDA has approved its use for children as well as adults. New research was just published demonstrating its helpfulness in treating children with nasal congestion (Oto-Open, April-June 2026). SoundHealth has underwritten The People's Pharmacy podcast. Dr. Nadeau has also been compensated for her role in conducting studies of this device (International Forum of Allergy & Rhinology, Dec. 2025). Since it does not employ medications, there are no drug side effects. This Week’s Guest Kari C. Nadeau, M.D., Ph.D., is Dean of the UCLA Fielding School of Public Health ( starting July 1 2026). Until then, she holds many other positions. At Harvard T. H. Chan School of Public Health she is: John Rock Professor of Climate and Population Studies; Chair of the Department of Environmental Health; and Director of the Allergy, Extreme Weather, and Exposomics Lab. Dr. Nadeau is Professor of Medicine at Harvard Medical School and serves in the Division of Allergy and Inflammation at Beth Israel Deaconess Medical Center. She is an Adjunct Professor at Stanford Medical School. Dr. Nadeau is also the co-author of The End of Food Allergy, which provides strategies for treating and preventing food allergies in children. Here is a link to the research underway in her Harvard laboratory. PHOTO CREDIT: STACY GEIKENTaken in April 2017 at Kari Nadeau’s professorship dinner The End of Food Allergy: The Science-Based Plan That Turns Food into Medicine The People's Pharmacy is reader supported. When you buy through links in this post, we may earn a small affiliate commission (at no cost to you). Listen to the Podcast The podcast of this program will be available Monday, June 8, 2026, after broadcast on June 6. You can stream the show from this site and download the podcast for free. This episode has additional information about Nasalcrom (cromolyn sodium nasal spray) and its effect on mast cells; alpha gal allergy to red meat; and the latest thinking on preventing peanut allergy among young children. Download the mp3

First quarter earnings are coming in at a rapid pace, with Sanofi and Novartis defending patents for Dupixent and Lutathera, respectively, and Sanofi welcoming Belén Garijo as CEO. Still to come this week are Eli Lilly, AstraZeneca, Regeneron and many more.Lilly will undoubtedly discuss its recent streak of dealmaking, including a $2.25 billion pact with AI biotech Profluent, plus buyouts of Ajax Therapeutics for up to $2.3 billion and Kelonia Therapeutics for up to $7 billion.Meanwhile, Regeneron earned FDA approval for the highly anticipated gene therapy that will now be known as Otarmeni. The same day the approval came down, Regeneron also struck a deal with the White House.Over at the FDA, the agency has requested—again—that Amgen remove the autoimmune therapy Tavneos from the market. Separately, the FDA has issued three Commissioner's National Priority Vouchers to unnamed psychedelic drug developers. Finally, who will replace Vinay Prasad, the head of the agency's Center for Biologics Evaluation and Research (CBER), who departs at the end of April after one year as the biologics chief?

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory updates that are shaping the future of the industry. At the latest meeting of the American Association for Cancer Research, innovative cancer therapies were in the spotlight. Merck showcased its PD-1xVEGF bispecific antibody for non-small cell lung cancer, combining immune checkpoint inhibition with anti-angiogenic strategies. This novel approach could enhance efficacy and safety compared to existing treatments. Despite these promising developments, Merck remains cautious about disclosing its Phase 3 trial plans, likely due to competitive pressures. The conference also featured industry veterans like Dr. Daniel Chen, who is pioneering "smart" cancer drugs through his startup. These antibody-drug conjugates aim to deliver targeted therapies with precision, minimizing off-target effects—a clear nod towards personalized medicine tailored to the genetic profiles of tumors. Revolution Medicines is making strides in targeting RAS mutations, particularly in pancreatic cancer, with its lead candidate daraxonrasib showing promise in Phase 3 trials. This positions the drug as a potential breakthrough for this challenging cancer type. Their broader pipeline suggests a strategic focus on exploiting RAS pathways, heralding a new wave of targeted cancer therapies. Meanwhile, National Cancer Institute Director Letai reassured attendees about stable research funding amidst political uncertainties, aiming to sustain momentum in cancer research advancements. Regulatory concerns were also a focal point at AACR. Dr. Richard Pazdur expressed anxiety over political influences impacting the U.S. FDA, reflecting broader challenges within regulatory frameworks that could affect drug approval processes and innovation timelines. On an international note, Zai Lab's global expansion ambitions were examined. Transitioning from licensing deals to independent biopharmaceutical development illustrates China's growing influence in biotech, though scaling operations across diverse regulatory environments presents significant challenges. In another significant development, Regeneron secured FDA approval for a pioneering gene therapy, underscoring rapid advances toward personalized therapies for genetic disorders. This marks a new era in genetic medicine and highlights the transformative potential of gene therapy. Meanwhile, Pfizer's strategic post-COVID-19 restructuring has resulted in further layoffs in Ireland, reflecting broader industry trends towards financial recalibration. Such moves underscore the ongoing adjustments companies face as they adapt to post-pandemic market dynamics. Pfizer's strategic portfolio management reflects a trend towards focusing resources on promising late-stage assets while deprioritizing earlier-stage projects that don't align with evolving goals. Roche's oral selective estrogen receptor degrader giredestrant remains a focal point despite clinical data concerns. Positioned as a potential major product in oncology, it illustrates the complexities involved in commercializing promising therapies amid data uncertainties. Sanofi continues to drive growth with Dupixent while preparing legal defenses to extend U.S. exclusivity beyond 2031—a strategic effort to protect revenue streams against generic competition. Conversely, AbbVie's attempt to introduce a Botox successor faced setbacks due to manufacturing-related issues flagged by the FDA, highlighting the complexities of meeting stringent regulatory standards. Avalyn Pharma's $182 million IPO signifies strong investor confidence in late-stage respiratory drug candidates, emphasizing efforts to innovate in chronic disease management. Regulatory dynamics are evolving too, with initiatives aimed at exSupport the show

Two-drug, single-tablet approved to replace current antiretroviral regimen; Dupixent approved for pediatric CSU; novel treatment significantly improves survival in metastatic pancreatic cancer; oral semaglutide for adolescents; GLP-1 Fast Tracked for knee osteoarthritis.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Regeneron has recently achieved a pivotal milestone with the FDA's approval of its hearing loss gene therapy, Otarmeni. This approval, facilitated through the FDA's Commissioner's National Priority Voucher Program, emphasizes the expanding recognition of gene therapies as essential therapeutic modalities. Otarmeni stands out as it directly targets an underlying genetic cause of hearing loss, marking a significant advancement in audiological medicine. Traditionally, hearing loss has been managed with hearing aids or cochlear implants, which do not address the root cause. Otarmeni represents a transformative approach by correcting genetic deficiencies, offering patients a chance for improved auditory function. This achievement not only highlights Regeneron's innovative capabilities but also sets a precedent encouraging other companies to explore genetic disorder treatments. Eli Lilly's development of AK-OTOF, targeting otoferlin deficiencies crucial for auditory processes, further signifies robust competition in this space. Currently under Phase 1/2 clinical trials, AK-OTOF is anticipated to continue research efforts until 2028. These advancements illustrate a promising pipeline of treatments that could potentially revolutionize patient care. The regulatory landscape is adapting to accommodate such novel therapies, with programs like the FDA's National Priority Voucher Program playing a crucial role in expediting access to groundbreaking treatments. From a scientific perspective, therapies like Otarmeni underscore the importance of understanding genetic mechanisms in disease pathogenesis. By modifying faulty genes within cells, these therapies offer hope not only for hearing loss but for a range of genetic disorders as well. Turning our attention to Novo Nordisk's progress with oral semaglutide for adolescent Type 2 diabetes; the company has announced positive clinical trial results extending its use beyond obesity treatment. This development is significant given the increasing prevalence of Type 2 diabetes among younger populations. Oral GLP-1 receptor agonists could revolutionize diabetes management by providing an alternative to injections, potentially improving compliance and quality of life for patients. In regulatory practices, there is a growing call for transparency. A citizen petition urges the FDA to refine disclosure protocols concerning Complete Response Letters (CRLs), aligning with industry demands for clarity in drug approval processes. Enhanced transparency could lead to more efficient regulatory pathways and strengthen trust between pharmaceutical companies and regulators. Roche's recent earnings report reveals challenges beyond currency fluctuations, as several key drugs underperformed against expectations. This raises questions about Roche's strategic positioning amid intense competition and market dynamics. Conversely, AbbVie's $1.4 billion investment in North Carolina to establish a new production base highlights strategic expansions aimed at meeting rising pharmaceutical demand. Technological innovation continues shaping industry strategies with Merck & Co.'s collaboration with Google Cloud aimed at enhancing AI capabilities—a $1 billion initiative focusing on transforming healthcare professional engagement through data analytics and AI insights. Such collaborations are likely to optimize marketing strategies and improve patient outcomes by facilitating personalized healthcare interactions. Meanwhile, Sanofi's defense of Dupixent amid R&D setbacks exemplifies how breakthrough biologics can drive revenue growth despite challenges. These developments highlight an industry undergoing transformation towards transparency, innovative treatments, strategic expansion, and technological adoption—promisingSupport the show

Glenmark to launch the first generic version of Flovent HFA, expanding affordable access; achondroplasia treatment granted accelerated approval; Dupixent approved for allergic fungal rhinosinusitis; and a swallowable balloon offers a unique outpatient alternative for weight management.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of developments that highlight the dynamism and complexity of our industry. The pharmaceutical and biotech sectors continue to evolve rapidly, driven by scientific innovations, regulatory shifts, and strategic initiatives.Eli Lilly's recent move to launch "Employer Connect," a platform aimed at improving access to its obesity medications, marks a significant step in addressing the growing public health issue of obesity. This initiative reflects the increasing influence of employer-driven healthcare solutions in managing chronic conditions. By directly involving employers, Eli Lilly seeks to enhance both the accessibility and affordability of its treatments, which could lead to better patient outcomes and reduced healthcare costs associated with obesity-related complications.In dermatology, Galderma has doubled its sales projections for Nemluvio (nemolizumab), an atopic dermatitis treatment, following a successful market debut. The revised projection to over $4 billion in peak annual sales underscores Nemluvio's strong market performance against competitors like Dupixent. This success not only highlights the drug's therapeutic efficacy but also indicates robust market demand for innovative dermatological therapies.Regulatory landscapes remain pivotal in shaping the industry. Vanda Pharmaceuticals' ongoing efforts to expand Hetlioz's label for jet lag treatment have been met with regulatory challenges since 2019. The FDA's response to Vanda's request for a public hearing underscores the complexities involved in navigating approval processes for label expansions. The outcome of such hearings could have broader implications for similar drugs seeking label amendments.Geopolitical dynamics also influence biopharma investments, with Ireland emerging as a stable manufacturing hub amidst global uncertainties. Despite geopolitical tensions, U.S. investments continue to flow into Ireland, highlighting its strategic importance as a location for biopharmaceutical manufacturing and innovation.In oncology, Pfizer is advancing its research and development strategy under Jeff Legos' leadership by leveraging its $43 billion acquisition of Seagen. The aim is to build an antibody-drug conjugate empire while advancing a PD-1xVEGF bispecific drug licensed from 3SBio. This approach underscores Pfizer's commitment to expanding its oncology pipeline through innovative therapies and combination regimens that could potentially transform cancer treatment paradigms.Meanwhile, Merck KGaA faces challenges with declining U.S. sales of Mavenclad due to anticipated generic competition. This situation reflects a broader industry trend where pharmaceutical companies must navigate patent expirations and generic market entries that threaten revenue streams of established products.Leo Pharma's launch of a direct-to-consumer campaign for Anzupgo, targeting hand eczema treatment, signifies the growing role of consumer engagement in pharmaceutical marketing strategies. Such approaches are becoming increasingly important in reaching patients directly.Collaborations remain a key driver of innovation within the industry. Daiichi Sankyo's partnership with German medtech Gaia to commercialize Lipodia—a digital therapeutic for high cholesterol management—illustrates the convergence between digital health technologies and traditional pharmaceuticals.In gene therapy news, uniQure finds itself in a contentious dialogue with the FDA over its Huntington's disease therapy. The debate centers around uniQure's claim that the FDA requested a "sham trial," which the agency denies. This situation underscores regulatory complexities surrounding gene therapies targeting rare diseases.Simultaneously, PepGen faces a partial clinical hold on its muscle wasSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

Ecoutez L'angle éco de François Lenglet du 19 février 2026.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Ecoutez L'angle éco de François Lenglet du 19 février 2026.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

If you're taking steroids, immunosuppressants, biologics like Dupixent, or JAK inhibitors for eczema, you may be wondering how these medications impact your gut and skin microbiome.In this episode, Julia breaks down what the research shows about how different eczema medications affect the immune system, skin barrier, and the gut.She covers: 4 common drug classes: Steroids, immunosuppressants, biologics, and JAK inhibitorsPotential benefits and risks How they may or may not impact the gut & skin microbiomeWhat you can do to support your body while on treatmentThis episode is not anti-medication. It's about understanding how to approach healing in a balanced way by supporting your microbiome, nutrition, and nervous system along with conventional care.Always consult your physician before making any changes to your medications.Work with Julia:⁠Book a Free Consultation⁠Follow Julia on her social⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠@juliachien.rd⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!

Dr. Jeni Hayes, Senior Clinical Manager, Strategic Clinical Intelligence, and Dr. Heather Pace, Senior Clinical Manager, Ambulatory Care, join host Carolyn Liptak to discuss the Vizient Winter 2026 Spend Management Outlook, with a focus on pharmacy projections and key changes from prior outlooks. The episode also covers ambulatory care and self-administered drugs, biosimilar therapeutic insights, and dynamic pharmacy market forces.   Guest speaker:     Jeni Hayes, PharmD, BCPS   Senior Clinical Manager, Strategic Clinical Intelligence Vizient Spend Management Solutions   Heather Pace, PharmD   Senior Clinical Manager, Ambulatory Care Vizient Center for Pharmacy Practice Excellence     Host:   Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director, Regulatory Compliance & Revenue Integrity Center for Pharmacy Practice Excellence (CPPE) Vizient   00:05 — Introduction Announcer welcomes listeners to Verified Rx, produced by the Vizient Center for Pharmacy Practice Excellence.   00:14 — Episode Overview Host Carolyn Liptak, Pharmacy Executive Director at Vizient, introduces the Winter 2026 Spend Management Outlook (SMO). Focus areas: Pharmacy inflation projections Acute vs ambulatory care trends Provider-administered vs self-administered drugs Biosimilar therapeutic insights Dynamic pharmacy market forces shaping 2026–2030 Guests: Jeni Hayes, Senior Clinical Manager, Strategic Clinical Intelligence Heather Pace, Senior Clinical Manager, Ambulatory Care   01:09 — What Is the Spend Management Outlook (SMO)? Biannual Vizient publication projecting price trends across healthcare spend categories. Pharmacy headline: Inflation slightly lower than last edition Total spend still rising, driven by utilization growth and new technologies   01:49 — Top-Line Pharmacy Inflation Projection 2.84% projected drug inflation for purchases between July 2026 – June 2027. Down from 3.35% in the prior edition. Based on October 2024 – September 2025 wholesaler data. Heavily weighted toward highest-spend drugs. Contracted products show lower inflation; non-contract drugs still ~70% of spend.   02:45 — Inflation by Site of Care Acute Care 3.03% projected inflation Driven by: Sugammadex Kcentra Clotting factors Ambulatory Care 2.85% overall, but with key divergence: Provider-administered drugs: 3.35% Self-administered drugs: 2.43%   04:02 — Provider-Administered Drugs: What's Driving Growth Oncology infusions are the main drivers. Key agents: Keytruda Darzalex Faspro Continued growth due to: Expanded indications Increased outpatient infusion utilization Oncology split by site of care: Inpatient: High-cost CAR T (e.g., Yescarta) Outpatient: Infusions, bispecifics, emerging cellular therapies Emphasizes importance of site of care strategy.   05:14 — Self-Administered Drugs: Utilization Over Inflation Five key drivers: Autoimmune / inflammatory: Skyrizi, Dupixent, Rinvoq Diabetes / metabolic / weight loss: Ozempic, Wegovy, Mounjaro, Zepbound Spend growth fueled by: Media exposure Expanded indications Increased patient demand Opportunity for: Retail & specialty pharmacy optimization Margin capture Patient support (adherence, counseling, benefits investigation)   06:45 — New Section: Dynamic Pharmacy Market Forces (2026–2030) Seven strategic forces influencing pharmacy practice: Growth in specialty and cell & gene therapies Expansion of value- and outcomes-based contracting Siteofcare shifts toward ambulatory and home Digital transformation & automation Supply assurance and resilience Expanded pharmacist clinical scope & workforce models Regulatory and policy efforts to lower drug prices 340B changes IRA Medicare Part D negotiations   09:37 — Practical Takeaways for Pharmacy Leaders Use 2.84% inflation as a baseline — then customize using Vizient Pharmacy Analytics. Leverage segmented views to prioritize: Acute vs ambulatory strategies Provider-administered vs self-administered drugs Identify top spend movers and align them with long-term market forces. Consider: Specialty pharmacy expansion Site of care optimization   10:48 — Biosimilar Therapeutic Insights: 2025 Recap Heather Pace highlights: Shift from biosimilar approval to active adoption management. Ustekinumab (Stelara) as defining example: Multiple biosimilars Uptake driven by payer and PBM strategy Utilization varies widely based on: Formulary design Benefit alignment Biosimilars now actively steered, not passively adopted.   11:50 — Why Stelara Was a Turning Point PBM-developed, private-label biosimilars drove adoption. Net cost and copay design outweighed: Interchangeability status Manufacturer differentiation Sets expectations for future biologic launches.   12:25 — Operational Impact for Health Systems Expect payer-specific product preferences. Frequent switching will become routine. Key considerations: Siteofcare mandates Product presentation Supply chain logistics Billing & reimbursement complexity Clinical barriers are decreasing; workflow flexibility is critical.   13:09 — What to Expect From Biosimilars in 2026 Faster adoption timelines Earlier payer-driven switching Fewer preferred products Less reliance on reference product trial periods   13:45 — Biosimilars With Major 2026 Impact Eylea — multiple launches expected post-litigation Xolair — expansion into asthma/allergy and retail specialty Perjeta — oncology pathway disruption expected late 2026 / early 2027   15:01 — 2025 Biosimilars Impacting 2026 Ustekinumab (Stelara): broader formulary shifts Denosumab (Prolia, Xgeva): full year of impact; all interchangeable Eculizumab (Soliris): first rare-disease biosimilar entry   15:58 — FDA Biosimilar Guidance to Watch Late-2025 FDA guidance: Reduced reliance on clinical efficacy trials Greater emphasis on analytical similarity Aims to: Reduce development cost Accelerate market entry   16:26 — Interchangeability: Where Things Are Headed Moving toward expectation that all biosimilars are interchangeable. Shifts responsibility to: Payers Health systems Pharmacists managing transitions and education   17:17 — Biggest Shift in the Biosimilar Landscape Faster launches Larger scale adoption Payer strategy more influential than timing of approval Success depends on: Formulary fit Channel alignment Operational simplicity   17:41 — Final Biosimilar Insight Biosimilar strategies must be molecule-specific. One-size-fits-all approaches are no longer effective.   18:13 — Final Thoughts on the SMO Inflation projections are a starting point. Leaders should: Focus on top spend drugs Understand siteofcare and specialty drivers Translate projections into actionable budgets   18:40 — Resources Winter 2026 Spend Management Outlook available on Vizient's SMO Hub. Includes current and prior editions and related insights.   18:58 — Closing Carolyn thanks Jeni and Heather. Reminder to subscribe, like, and share feedback. Verified Rx is produced by the Vizient Center for Pharmacy Practice Excellence.   Links | Resources:  Vizient Spend Management Outlook webpage Vizient Winter 2026 Spend Management Outlook Vizient Biosimilars Therapeutic Insights   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed    

This is the 71st episode in my drug pronunciation series. In this episode, I divide Dupixent and dupilumab into syllables, tell you which syllables to emphasize, and share my sources. The written pronunciations are below and in the show notes on https://www.thepharmacistsvoice.com.   EoE is mentioned in this episode. To learn more about eosinophilic esophagitis, watch the following YouTube video: https://bit.ly/4pplm8w    Note: we don't cover pharmacology in this series. Just pronunciations.   We're changing to a new format in February 2026! Click to sign up for The Pharmacist's Voice® monthly email newsletter to get notified about each new (MONTHLY) episode. https://bit.ly/3AHJIaF    Dupixent = DU-pix-ent DU, like dual pix, like pixel ent, like [part of] the last syllable of the word, president  Emphasize DU Written Pronunciation Source: Dupixent's Patient information on the Regeneron's Website https://www.regeneron.com/downloads/dupixent_ppi.pdf (accessed 1-5-26) Spoken Pronunciation Example: Dupixent injection demonstration video - first 20 sec on dupixent.com (accessed 1-5-26) and Dupixent's YouTube channel https://www.youtube.com/@DUPIXENT (accessed 1-5-26)   dupilumab = doo-PIL-ue-mab Du, like dual PIL, like pillow ue, like the letter in the alphabet, "U' mab, which is the stem for monoclonal antibodies  Emphasize PIL Written pronunciation source: USP Dictionary Online and MedlinePlus.gov   Spoken Pronunciation Examples: Podcast episodes on Dupixent's YouTube channel (in the first 20 sec) and Dupixent injection demonstration video - in the first 20 sec on dupixent.com.   If you know someone who would like to learn how to say Dupixent and dupilumab, please share this episode with them. Subscribe for all future episodes. This podcast is on all major podcast players and YouTube. Popular links are below. ⬇️   Apple Podcasts   https://apple.co/42yqXOG  Spotify  https://spoti.fi/3qAk3uY  Amazon/Audible  https://adbl.co/43tM45P YouTube https://bit.ly/43Rnrjt   Host Background: Kim Newlove has been an Ohio pharmacist since 2001 (BS Pharm, Chem Minor). Her experience includes hospital, retail, compounding, and behavioral health. She is also an author, voice actor (medical narrator and audiobook narrator), podcast host, and consultant (audio production and podcasting).    Other episodes in this series The Pharmacist's Voice Podcast Episode 362, Pronunciation Series Episode 70 (Corlanor) The Pharmacist's Voice Podcast Episode 360, Pronunciation Series Episode 69 (Kisunla) The Pharmacist's Voice Podcast Episode 358, Pronunciation Series Episode 68 (Journavx) The Pharmacist's Voice Podcast Episode 356, Pronunciation Series Episode 67 (Zanaflex) The Pharmacist's Voice Podcast Episode 352, Pronunciation Series Episode 66 (Yescarta) The Pharmacist's Voice Podcast Episode 350, Pronunciation Series Episode 65 (Xarelto) The Pharmacist's Voice Podcast Episode 349, Pronunciation Series Episode 64 (acetaminophen) The Pharmacist's Voice Podcast Episode 348, Pronunciation Series Episode 63 (Welchol/colesevelam) The Pharmacist's Voice Podcast Episode 346, Pronunciation Series Episode 62 (valacyclovir) The Pharmacist's Voice Podcast Episode 343, Pronunciation Series Episode 61 (ubrogepant) The Pharmacist's Voice Podcast Episode 341, Pronunciation Series Episode 60 (topiramate) The Pharmacist's Voice Podcast Episode 339, Pronunciation Series Episode 59 (Suboxone) The Pharmacist's Voice Podcast Episode 337, Pronunciation Series Episode 58 (rosuvastatin)  The Pharmacist's Voice Podcast Episode 335, Pronunciation Series Episode 57 (QVAR) The Pharmacist's Voice Podcast Episode 333, Pronunciation Series Episode 56 (pantoprazole)  The Pharmacist's Voice Podcast Episode 330, Pronunciation Series Episode 55 (oxcarbazepine) The Pharmacist's Voice Podcast Episode 328, Pronunciation Series Episode 54 (nalmefene) The Pharmacist's Voice Podcast Episode 326, Pronunciation Series Episode 53 (Myrbetriq) The Pharmacist's Voice Podcast Episode 324, Pronunciation Series Episode 52 (liraglutide)  The Pharmacist's Voice Podcast Episode 322, Pronunciation Series Episode 51 (ketamine) The Pharmacist's Voice Podcast Episode 320, Pronunciation Series Episode 50 (Jantoven) The Pharmacist's Voice Podcast Episode 318, Pronunciation Series Episode 49 (ipratropium) The Pharmacist's Voice Podcast Episode 316, Pronunciation Series Episode 48 (hyoscyamine) The Pharmacist's Voice Podcast Episode 313, Pronunciation Series Episode 47 (guaifenesin) The Pharmacist's Voice Podcast Episode 311, Pronunciation Series Episode 46 (fluticasone) The Pharmacist's Voice Podcast Episode 309, Pronunciation Series Episode 45 (empagliflozin) The Pharmacist's Voice Podcast Episode 307, Pronunciation Series Episode 44 (dapagliflozin) The Pharmacist's Voice Podcast Episode 304, Pronunciation Series Episode 43 (cetirizine)  The Pharmacist's Voice Podcast Episode 302, Pronunciation Series Episode 42 (buspirone)  The Pharmacist's Voice Podcast Episode 301, Pronunciation Series Episode 41 (azithromycin) The Pharmacist's Voice Podcast Episode 298, Pronunciation Series Episode 40 (umeclidinium) The Pharmacist's Voice Podcast Episode 296, Pronunciation Series Episode 39 (Januvia)  The Pharmacist's Voice Podcast Episode 294, Pronunciation Series Episode 38 (Yasmin) The Pharmacist's Voice Podcast Episode 292, Pronunciation Series Episode 37 (Xanax, alprazolam) The Pharmacist's Voice Podcast Episode 290, Pronunciation Series Episode 36 (quetiapine)  The Pharmacist's Voice Podcast Episode 287, pronunciation series ep 35 (bupropion) The Pharmacist's Voice Podcast Episode 285, pronunciation series ep 34 (fentanyl) The Pharmacist's Voice Podcast Ep 281, Pronunciation Series Ep 33 levothyroxine (Synthroid) The Pharmacist's Voice ® Podcast Ep 278, Pronunciation Series Ep 32 ondansetron (Zofran) The Pharmacist's Voice ® Podcast Episode 276, pronunciation series episode 31 (tocilizumab-aazg) The Pharmacist's Voice ® Podcast Episode 274, pronunciation series episode 30 (citalopram and escitalopram) The Pharmacist's Voice ® Podcast Episode 272, pronunciation series episode 29 (losartan) The Pharmacist's Voice Podcast Episode 269, pronunciation series episode 28 (tirzepatide) The Pharmacist's Voice Podcast Episode 267, pronunciation series episode 27 (atorvastatin)  The Pharmacist's Voice Podcast Episode 265, pronunciation series episode 26 (omeprazole) The Pharmacist's Voice Podcast Episode 263, pronunciation series episode 25 (PDE-5 inhibitors) The Pharmacist's Voice Podcast Episode 259, pronunciation series episode 24 (ketorolac) The Pharmacist's Voice ® Podcast episode 254, pronunciation series episode 23 (Paxlovid) The Pharmacist's Voice ® Podcast episode 250, pronunciation series episode 22 (metformin/Glucophage) The Pharmacist's Voice Podcast ® episode 245, pronunciation series episode 21 (naltrexone/Vivitrol) The Pharmacist's Voice ® Podcast episode 240, pronunciation series episode 20 (levalbuterol) The Pharmacist's Voice ® Podcast episode 236, pronunciation series episode 19 (phentermine)  The Pharmacist's Voice ® Podcast episode 228, pronunciation series episode 18 (ezetimibe) The Pharmacist's Voice ® Podcast episode 219, pronunciation series episode 17 (semaglutide) The Pharmacist's Voice ® Podcast episode 215, pronunciation series episode 16 (mifepristone and misoprostol) The Pharmacist's Voice ® Podcast episode 211, pronunciation series episode 15 (Humira®) The Pharmacist's Voice ® Podcast episode 202, pronunciation series episode 14 (SMZ-TMP) The Pharmacist's Voice ® Podcast episode 198, pronunciation series episode 13 (carisoprodol) The Pharmacist's Voice ® Podcast episode 194, pronunciation series episode 12 (tianeptine) The Pharmacist's Voice ® Podcast episode 188, pronunciation series episode 11 (insulin icodec)  The Pharmacist's Voice ® Podcast episode 184, pronunciation series episode 10 (phenytoin and isotretinoin) The Pharmacist's Voice ® Podcast episode 180, pronunciation series episode 9 Apretude® (cabotegravir) The Pharmacist's Voice ® Podcast episode 177, pronunciation series episode 8 (metoprolol)  The Pharmacist's Voice ® Podcast episode 164, pronunciation series episode 7 (levetiracetam) The Pharmacist's Voice ® Podcast episode 159, pronunciation series episode 6 (talimogene laherparepvec or T-VEC)  The Pharmacist's Voice ® Podcast episode 155, pronunciation series episode 5 Trulicity® (dulaglutide)  The Pharmacist's Voice ® Podcast episode 148, pronunciation series episode 4 Besponsa® (inotuzumab ozogamicin) The Pharmacist's Voice ® Podcast episode 142, pronunciation series episode 3 Zolmitriptan and Zokinvy The Pharmacist's Voice ® Podcast episode 138, pronunciation series episode 2 Molnupiravir and Taltz The Pharmacist's Voice ® Podcast episode 134, pronunciation series episode 1 Eszopiclone and Qulipta   Kim's websites and social media links: ✅ Guest Application Form (The Pharmacist's Voice Podcast) https://bit.ly/41iGogX ✅ Monthly email newsletter sign-up link https://bit.ly/3AHJIaF  ✅ LinkedIn Newsletter link https://bit.ly/40VmV5B ✅ Business website https://www.thepharmacistsvoice.com ✅ Get my FREE eBook and audiobook about podcasting ✅ The Pharmacist's Voice ® Podcast https://www.thepharmacistsvoice.com/podcast ✅ Drug pronunciation course https://www.kimnewlove.com  ✅ Podcasting course https://www.kimnewlove.com/podcasting  ✅ LinkedIn https://www.linkedin.com/in/kimnewlove ✅ Facebook https://www.facebook.com/kim.newlove.96 ✅ Twitter https://twitter.com/KimNewloveVO ✅ Instagram https://www.instagram.com/kimnewlovevo/ ✅ YouTube https://www.youtube.com/channel/UCA3UyhNBi9CCqIMP8t1wRZQ ✅ ACX (Audiobook Narrator Profile) https://www.acx.com/narrator?p=A10FSORRTANJ4Z ✅ Start a podcast with my coach, Dave Jackson from The School of Podcasting! *New 12-4-25* Click my affiliate link: https://community.schoolofpodcasting.com/invitation?code=G43D3G    Thank you for listening to episode 364 of The Pharmacist's Voice ® Podcast.  If you know someone who would like this episode, please share it with them!

Mark Fadel, MD joins this episode of Head & Neck Innovations to discuss recent advances and innovations he is excited about as he starts his practice in pediatric otolaryngology. Advancements in medical treatments like Dupixent and Trikafta are transforming care for children with allergic rhinitis and cystic fibrosis—reducing the need for surgery and improving outcomes.

Send us a textGood morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking changes and innovations reshaping the landscape of drug development, clinical trials, and regulatory affairs.In a major move, Pfizer has successfully outbid Novo Nordisk to acquire Metsera for $10 billion. This strategic acquisition aims to bolster Pfizer's presence in the obesity treatment market by leveraging Metsera's GLP-1 receptor agonist technology. This acquisition underscores the continuing trend of consolidation within the pharmaceutical industry, enhancing competitive market positioning and reflecting a broader quest for novel therapeutic solutions.Eli Lilly has entered into a $1.2 billion collaboration with Sangenebio to advance RNA interference (RNAi) therapeutics targeting metabolic diseases. This partnership marks a pivotal shift towards utilizing RNAi technology to silence disease-causing genes, representing significant progress in metabolic disease treatment. The focus on innovative delivery mechanisms and targeted interventions is critical for accelerating drug development and enhancing therapeutic efficacy.Onchilles Pharma's recent Series A1 funding round, securing $25 million, marks a notable advancement in oncology therapeutics. The company's focus on dual-action cancer biologics targeting the ELANE pathway offers promising insights into immune activation in solid tumors. This investment exemplifies the growing interest in biologic therapies that provide targeted cancer treatments, potentially leading to more effective options for patients.Regulatory advancements are also making headlines. Chongqing Precision Biotech has received approval for Pujiolunxi, a treatment for pediatric relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), broadening therapeutic options for this challenging pediatric condition. Furthermore, Alembic Pharmaceuticals' generic version of Dasatinib tablets has gained FDA approval for Philadelphia chromosome-positive chronic myeloid leukemia, increasing accessibility to treatment.Several promising clinical trial results have emerged recently. Summit Therapeutics and Akeso Biopharma's Ivonescimab showed a 26% overall survival benefit in phase 3 trials for non-small-cell lung cancer. The potential of bispecific antibodies in combination therapies is gaining attention for its efficacy in difficult-to-treat cancers. Additionally, Regeneron's Dupixent has achieved phase 3 success in treating allergic fungal rhinosinusitis, reinforcing its role as a versatile treatment option across various inflammatory diseases.Advancements in cardiovascular therapeutics also continue to unfold. Merck & Co.'s Enlicitide Decanoate demonstrated over 50% LDL cholesterol reduction in a phase 3 study focused on atherosclerotic cardiovascular disease through PCSK9 inhibition. AstraZeneca's Baxdrostat showed significant blood pressure reduction in trials targeting treatment-resistant hypertension, highlighting the potential impact of aldosterone synthase inhibitors on cardiovascular health.The investment landscape remains robust with substantial fundraising activities such as Elephas Biosciences' $40 million Series B-2 for commercializing their live tumor profiling platform and Iambic's over $100 million series focused on AI-driven drug discovery. These investments underscore the industry's commitment to integrating advanced technologies like AI and live tumor profiling to enhance precision medicine capabilities.FDA regulatory updates are pivotal as well, notably with the decision to lift warning labels from hormone replacement therapy (HRT) products following an expert review that found previous warnings were based on misinformation regaSupport the show

One of biopharma's most memorable bidding wars finally came to an end on Friday—with Metsera right back in the arms of its original suitor, but with Pfizer paying around $10 billion for the rights to the obesity biotech, a nearly $3 billion increase over its original bid. But while Novo Nordisk may have bowed out of that race, the company still made headlines this past week, with CEO Maziar Mike Doustdar joining Eli Lilly head David Ricks at the White House on Thursday to announce a deal that will see their GLP-1 drugs offered at about $350 per month.   This marks a significant discount to the current list prices of $1086 and $1350 for Lilly's obesity drug Zepbound and Novo's comparator Wegovy, respectively. No matter how low they go, however, the GLP-1 leaders can still be undercut by compounders, Steven Grossman, policy and regulatory consultant and author of the FDA Matters blog, told BioSpace this week.   Speaking of Lilly, the Indianapolis-based pharma had a busy week, reporting 20% weight loss in a mid-stage study of its amylin agonist eloralintide that William Blair analysts said “validates [the] amylin agonist class.” Lilly also netted two new partners, inking a $1.2 billion RNAi pact with SangeneBio to target metabolic diseases and licensing a genetic eye disease therapy from MeiraGTx Holdings for up to $475 million.   On the regulatory front, the FDA awarded the second round of priority review vouchers under its new Commissioner's National Priority Vouchers program. Unlike the first cohort of vouchers, which was announced in October, this group mostly consisted of products already on the market—with the exception of Lilly's orforglipron.   Finally, BioSpace dives into one the hottest trends in the immunology and inflammation (I&I) space—pipeline-in-a-product. Possibly motivated by blockbuster drugs like AbbVie's Skyrizi and Rinvoq and Regeneron and Sanofi's Dupixent, companies are optimizing shots on multiple goals in this lucrative space.  

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's rapidly evolving landscape, we witness significant strides shaping the future of drug development, patient care, and global market dynamics.Merck & Co. has made a notable advancement in cholesterol management with a PCSK9-targeted pill. This pill has achieved reductions in low-density lipoprotein cholesterol (LDL-C) comparable to existing injectable therapies. Such innovation represents a significant step forward by potentially offering a more convenient oral alternative for patients. The development underscores the industry's ongoing efforts to enhance patient compliance and therapeutic outcomes through novel drug delivery mechanisms.In a strategic corporate move, Pfizer has successfully acquired Metsera, an obesity biotech company, for a substantial $10 billion. This acquisition, which followed an intense bidding war with Novo Nordisk, exemplifies Pfizer's aggressive expansion in the obesity treatment market—a growing global health challenge. The strategic buyout positions Pfizer to leverage Metsera's expertise, potentially accelerating the development and commercialization of innovative obesity treatments.Meanwhile, Novo Nordisk is enhancing its presence in India by partnering with Emcure Pharmaceuticals to expand access to Wegovy, its weight-loss treatment. This collaboration is particularly significant given India's escalating obesity rates and highlights the importance of regional partnerships in enhancing drug accessibility and addressing public health issues.Regulatory developments continue to influence industry dynamics as well. The FDA has postponed its decision on expanding Rhythm Pharmaceuticals' Imcivree for additional indications. These regulatory delays highlight the complexities and unpredictabilities inherent in drug approval processes, underscoring the need for companies to strategically navigate these challenges.Regeneron and AstraZeneca have reported clinical trial successes with their respective anti-inflammatory drugs, Dupixent and Fasenra. These positive outcomes were showcased at the American College of Allergy, Asthma, and Immunology's annual meeting, bolstering the companies' aspirations for FDA approvals. Successful clinical outcomes not only pave the way for expanded therapeutic options but also demonstrate the industry's commitment to addressing complex inflammatory conditions.October has seen a surge in TV advertising spending, led by Johnson & Johnson's campaign for Tremfya. The campaign highlights the power of patient community engagement in bringing attention to conditions like inflammatory bowel disease (IBD), emphasizing how patient advocacy can reduce isolation among sufferers.In oncology, Cogent Biosciences is on track for an FDA submission following successful phase 3 trials of its cancer asset bezuclastinib. This development illustrates the critical role of rigorous clinical research in advancing oncology treatments and potentially improving patient outcomes.Turning our attention to technological frontiers within pharmaceutical R&D, Eli Lilly has been particularly active in cementing its commitment to artificial intelligence (AI) and gene therapy through several strategic collaborations. The company has entered into a $100 million-plus research agreement with Insilico Medicine to leverage AI for drug discovery. This partnership aims to expedite the identification of novel therapeutic targets and enhance drug development efficiency—a reflection of a broader industry trend towards integrating AI into pharmaceutical processes.Additionally, Lilly has made a notable move in gene therapy by acquiring rights from MeiraGTx for a retinal disease therapy that has shown Support the show

 This episode was created in collaboration with, and first posted on, The Itch podcast. Mucus plugging is a challenge in asthma care. It's thick, sticky mucus that blocks the airways and doesn't respond to regular inhalers. Even when inflammation improves, these plugs can lower lung function, limit how well medicine works, and make asthma harder to control. In this episode, The Itch breaks down the study: “Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma,” published Oct. 28, 2025. The analysis looks at whether dupilumab (Dupixent), a biologic that blocks IL-4 and IL-13, can lower mucus burden and improve lung function, especially in people who start with a high “mucus plug score.” Read the paper: https://www.atsjournals.org/doi/abs/10.1164/rccm.202410-1894OC 

Episode 205: Atopic Dermatitis Kara Willbanks (medical student) explains the definition, pathophysiology, and treatment of eczema. Dr. Arreaza adds some input about bleach baths and topical steroids. Written by Kara Willbanks, MSIV, American University of the Caribbean. Comments and edits by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.October is the Eczema Awareness Month!What Is Atopic Dermatitis? Atopic dermatitis, a form of eczema, is a chronic, relapsing inflammatory skin disorder that often begins in childhood but can affect people of all ages. Other eczematous dermatoses include seborrheic dermatitis, contact dermatitis, juvenile plantar dermatosis, and stasis dermatitis. Atopic dermatitis is one of the most common skin conditions in the developed world, typically affecting up to 20% of children and 5-10% of adults. Patients usually present with severe pruritus (itchiness) and dry, inflamed patches of skin. Common sites include the face and extensor surfaces in infants, and flexural areas — like the elbows and knees — in older children and adults. Atopic dermatitis is often associated with other allergic conditions like asthma and allergic rhinitis — what we call the “atopic triad.” These conditions should also be considered when diagnosing someone with atopic dermatitis. PathophysiologyAtopic dermatitis is believed to occur due to a combination of genetic, immune, and environmental factors. A major component is a defective skin barrier, often linked to mutations in the filaggrin gene. This allows irritants, allergens, and microbes to penetrate the skin more easily, triggering inflammation.Differential DiagnosisAtopic dermatitis can sometimes mimic other skin conditions, so it's important to keep a differential in mind: -Contact dermatitis – triggered by allergens or irritants; often limited to the area of exposure but also tends to be very itchy. -Seborrheic dermatitis – greasy scales, typically on the scalp, eyebrows, and nasolabial folds -Psoriasis – well-demarcated plaques with silvery scales; sometimes found in similar areas of the body as eczema. -Tinea (fungal infections) – ring-shaped lesions with active, scaly borders -Important to note that treatment of tinea with topical steroids can make the rash much worse. -Scabies – intense itching, especially at night, with burrows between fingers. Ruling out these conditions helps guide the right treatment and prevent chronic mismanagement. As a recap our main differential diagnosis: contact dermatitis, seborrheic dermatitis, psoriasis, tinea, and scabies.The treatment cornerstone: Moisturizers The most important daily treatment for atopic dermatitis is regular moisturizing. Moisturizers repair the skin barrier, reduce water loss, and protect against irritants. They should be applied at least twice daily, ideally right after bathing while the skin is still damp (within 3 minutes is most ideal). Use greasy ointments or thick creams rather than lotions — think products with ceramides or glycerin (hydrates and protects skin). It is best to choose ointments or creams without additives, perfumes or fragrances. Greasier ointments are the preferred vessel; however, patient compliance may be less as they may be unpleasant to some.Bleach Baths For patients with frequent skin infections or severe eczema, dilute bleach baths can be a game-changer. How to do it? Use ¼ to ½ cup of household bleach in a full standard bathtub of water (about 40 gallons) and soak for 10 minutes, twice a week. This helps reduce bacterial colonization — particularly Staphylococcus aureus — which commonly worsens eczema. After the bath, pat the skin dry and immediately apply a moisturizer (within 3 minutes). Bleach baths are endorsed by the American Academy of Pediatrics and the American Academy of Dermatology as an adjunctive treatment for atopic dermatitis, especially in patients with moderate to severe disease and frequent bacterial infections, but the evidence for their efficacy is mixed, and further well-designed studies are needed.Medical Treatments-Topical corticosteroids: When moisturizers alone aren't enough, we move to anti-inflammatory therapy. Topical corticosteroids are the first-line treatment for flares. Some studies suggest that a short burst of a high-potency topical corticosteroid to rapidly control active disease, followed by a quick taper in potency, is most effective, whereas others use the lowest-potency agent thought to be needed and adjust upward only if this fails. Common steroids used are hydrocortisone (low potency), triamcinolone (medium potency), or betamethasone (high potency). -High-potency steroids should never be applied to sensitive skin like the face. With short-term use of lower-potency steroids, there is a low likelihood of skin atrophy but use for more than 6 months is linked with greater levels of skin thinning -Wet wrap therapy: Wet wrap therapy improves absorption of topic steroid. Apply a topical steroid, then layer a wet dressing and then a dry dressing over the top of that. This can be beneficial in providing  both relief of symptoms and prevention of itching. In pediatric patients it is called “daddy's socks therapy” because large socks may be used to cover the arms of kids.-Topical calcineurin inhibitors — like tacrolimus — are great alternatives for sensitive areas or for maintenance once inflammation is under control. They may burn upon application which can scare patients away from their use.-PO antihistamines can help with itching, especially at night, but they don't treat inflammation itself.-Systemic therapies, like dupilumab (Dupixent®), an IL-4 receptor antagonist, are reserved for moderate to severe cases unresponsive to topical therapy. This is a great time to refer to your local dermatologist for management! Many of the newer treatments are highly effective but can require more frequent monitoring.Recent Research One recent study is the 2024 Cochrane network meta-analysis comparing effectiveness of topical anti-inflammatory treatments for eczema that was recently published in the AFP Journal in July of 2025.Here are the highlights:-Over 291 RCTs with ~45,846 participants were included. -The analysis ranked potent topical corticosteroids, JAK inhibitors (for example ruxolitinib (Opzelura® 1.5 %), and tacrolimus 0.1 % among the most effective for reducing signs and symptoms of eczema. -In contrast, PDE-4 inhibitors [like crisaborole (Eucrisa®) 2 %] were among the least effective in this comparison. -Regarding side effects: tacrolimus and crisaborole were more likely to cause burning or stinging at the application site; corticosteroids were less likely in the short term to cause local irritation.-Long-term outcomes regarding effectiveness or safety of treatments for eczema were not addressed by the review because they are rarely reported.”-Another insight from this study is considering cost when initiating treatment. Most topical steroids are significantly more cost effective than JAK inhibitors or calcineurin inhibitors so it may be best to start with a cheaper solution in an uninsured patient considering their relative effectiveness. Additional Tips & Lifestyle -Keep baths and showers short and in lukewarm water.-Avoid harsh soaps and detergents — use gentle, fragrance-free cleansers.-Wear soft cotton clothing instead of wool or synthetics.-Identify and avoid triggers — common ones include stress, sweating, allergens, and certain foods (especially in kids).-Ice packs can help reduce itching and relieve any burning sensation.-Keep fingernails short, especially in children, help cause less trauma to the skin from repeated itching. Living with eczema Many celebrities like Kerry Washington, Jessica Simpson, Kelly Rowland, Brad Pitt and Kristen Bell have spoken out about their lives with eczema. They have shared personal stories about how they were diagnosed, what treatment works for them, and the general impact it has had on their lives and mental health. I feel like it can be so important for celebrities to speak out about their lives with certain conditions because it helps to normalize the condition, raise awareness of the struggles, and encourages more open dialogue.It is important to remember that for patients living with eczema, the persistent itch-scratch cycle can be very distressing, causing patients to struggle with their sleep and day-to-day activities. Anxiety and depression are common in patients with eczema so as physicians it is vital to monitor for signs of distress. Support groups can be incredibly helpful for patients [National Eczema Association]If you are interested in providing additional information to your patients or getting this for yourself, you can find more resources on altogethereczema.org or nationaleczema.org. Key Takeaways Atopic dermatitis is chronic but manageable. Moisturizers are the foundation of treatment. Topical steroids and calcineurin inhibitors control inflammation. Bleach baths help reduce bacterial load and flare severity. Always rule out other skin conditions to ensure appropriate management. Atopic dermatitis can be managed by the primary care physician but in certain cases (cases refractory to standard topical treatment, recurrent infections, etc.), a referral to dermatology can be especially helpful.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! References:Coping with eczema. Allergy & Asthma Network. (2025, May 20). https://allergyasthmanetwork.org/what-is-eczema/coping-with-eczema/.Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014 Feb;70(2):338-51. doi: 10.1016/j.jaad.2013.10.010. Epub 2013 Nov 27. PMID: 24290431; PMCID: PMC4410183. https://pubmed.ncbi.nlm.nih.gov/24290431/.Yancey, J. R., & Green, S. (2025, July 15). Effectiveness of topical anti-inflammatory drugs for eczema. American Family Physician. https://www.aafp.org/pubs/afp/issues/2025/0700/cochrane-eczema.html.Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Mucus plugging is a challenge in asthma care. It's thick, sticky mucus that blocks the airways and doesn't respond to regular inhalers. Even when inflammation improves, these plugs can lower lung function, limit how well medicine works, and make asthma harder to control. In this episode, we break down the study: “Effect of Dupilumab on Mucus Burden in Patients with Moderate-to-Severe Asthma,” published October 28, 2025. The analysis looks at whether dupilumab (Dupixent), a biologic that blocks IL-4 and IL-13, can lower mucus burden and improve lung function, especially in people who start with a high “mucus plug score.” What we cover in our episode about dupilumab and mucus plugging Why mucus plugging matters in asthma: Discover how thick, sticky mucus can block airways, make it harder to breathe, and why standard inhalers and steroids don't clear these plugs. How dupilumab may help: Learn how this biologic blocks IL-4 and IL-13, two key drivers of type 2 inflammation that increase mucus production and thickness. Inside the VESTIGE study: Hear how researchers measured mucus burden using CT scans and “mucus plug scores” to see if dupilumab could reduce plugging in moderate-to-severe asthma. What the results showed: Find out how dupilumab lowered mucus plug scores, reduced airway inflammation, and improved lung function (FEV₁), especially in people with high mucus burden. What this means for patients: Learn why identifying and treating mucus plugging may help improve breathing, reduce flare-ups, and make asthma easier to manage day to day.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into some of the most significant shifts and strategies shaping our industry.Novartis's acquisition of Avidity Biosciences for a staggering $12 billion marks a pivotal moment in the pharmaceutical landscape this year. With this acquisition, Novartis underscores its commitment to bolstering its neuromuscular disease pipeline. Avidity Biosciences has made a name for itself with its cutting-edge RNA therapeutic technologies, particularly its Antibody Oligonucleotide Conjugates (AOCs). This platform uniquely combines monoclonal antibodies with oligonucleotides, enhancing precision in targeting specific cell types. The integration of Avidity's technology into Novartis's research efforts could accelerate the development of new therapies, potentially transforming patient care with more effective and targeted treatment options. This move not only highlights the industry's focus on specialized therapeutic areas but also anticipates future advances in RNA therapeutics, extending beyond neuromuscular disorders to areas like oncology.In a similar vein, the FDA has shown its willingness to reconsider drugs that previously faced setbacks. GSK's Blenrep has made a return to the U.S. market after receiving approval for treating certain myeloma patients. This approval is particularly noteworthy given the drug's earlier negative advisory committee vote and postponed decision. It marks a significant rebound for GSK's oncology portfolio and reflects the FDA's dynamic approach towards drugs that show potential in specific therapeutic combinations.Meanwhile, Sanofi continues to make waves with Dupixent, achieving over €4 billion in quarterly sales due to its expanded indications. This success contrasts with a decline in Sanofi's vaccine sales, demonstrating shifting dynamics within pharmaceutical portfolios where biologics and specialty drugs are increasingly pivotal. Sanofi's recent financial report highlighted a notable 17% drop in vaccine sales due to reduced demand and pricing challenges in Europe. In response, companies must navigate fluctuating public health demands and economic pressures effectively.On the global stage, efforts to make transformative therapies like Vertex's Trikafta more accessible are gaining momentum through innovative trade-policy workarounds. A buyers club aims to introduce a lower-cost alternative produced by Bangladesh's Beximco, highlighting ongoing challenges and creative strategies in global drug accessibility.Roche's expansion through Chugai's $200 million M&A deal for an IgA nephropathy asset underscores the strategic importance of regional markets in driving growth. Similarly, Lonza's acquisition of a California biologics site aligns with its goals to meet increasing biomanufacturing demands.The industry is also adapting to technological advancements, with AI integration into life sciences commercialization being touted as a frontier for growth. Despite this potential, many organizations remain unprepared to harness AI fully. Leading companies embedding AI solutions aim for measurable outcomes that could significantly drive strategic decision-making and operational efficiencies.Eli Lilly's acquisition of Adverum Biotechnologies aligns with its strategic interests in gene therapy, focusing on promising therapeutic programs that address unmet medical needs. This acquisition centers around Ixo-vec for wet age-related macular degeneration (AMD), highlighting broader industry trends towards investing heavily in innovative therapies that address unmet needs.Conversely, Sanofi's halt on an RSV vaccine development highlights the inherent risks in vaccine development pipelines. Meanwhile, Regeneron's decision to discontinue a CAR T candidate acquired from 2seventy bio showcases ongoing reassessment witSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers, and strategic investments.One notable event was AstraZeneca and Daiichi Sankyo's success at the European Society for Medical Oncology Congress 2025. Their antibody-drug conjugate, Datroway, demonstrated superior efficacy compared to Gilead's Trodelvy in the first global head-to-head trial involving Trop2-targeted therapies. This reflects the increasing focus on antibody-drug conjugates as precision medicine tools that offer targeted treatment options with potentially improved outcomes over traditional chemotherapy.In a move highlighting the ongoing trend of bolstering domestic production capacities, Merck is making a substantial $3 billion investment in a small molecule drug plant in Virginia. This is part of a broader $70 billion commitment to expand manufacturing and R&D capabilities in the U.S. Such strategic investments are crucial for maintaining competitive advantage and ensuring drug availability while meeting rising demands and streamlining supply chains.Turning to regulatory updates, the FDA has approved Amgen and AstraZeneca's Tezspire for chronic rhinosinusitis with nasal polyps. This marks Tezspire's second indication, following its initial approval for severe asthma in 2021. The expanded approval showcases the drug's versatility and represents a strategic push to enhance its market presence against competitors like Dupixent.In oncology, Merck's Keytruda and Astellas/Pfizer's Padcev have made headlines with compelling results in muscle-invasive bladder cancer. The combination therapy reduced the risk of death by 50%, reinforcing Keytruda's position as a cornerstone immunotherapy across multiple cancer types. This result not only augments treatment options but also signifies the potential for combination regimens to enhance patient outcomes.Roche has expanded the indication of its aging oncology drug Gazyva to treat lupus nephritis, demonstrating strategic repurposing efforts to extend the lifecycle of existing therapies. While this expansion into autoimmune diseases comes late in Gazyva's lifecycle, it highlights a growing trend of capitalizing on established drugs for new therapeutic areas.AstraZeneca and Daiichi Sankyo's Enhertu showed robust efficacy in early breast cancer treatment, potentially reshaping therapeutic strategies by offering new hope for early intervention. Similarly, Novartis' Pluvicto demonstrated promise in slowing hormone-sensitive prostate cancer progression, underscoring the potential of radioligand therapies in oncology.However, not all developments have been positive. AstraZeneca faced setbacks when its Imfinzi and Lynparza combination failed to meet survival goals in ovarian cancer, underscoring the challenges inherent in oncology drug development and the stringent benchmarks set by regulatory authorities like the FDA.The industry is also witnessing significant advancements in next-generation ADCs, as evidenced by Tubulis' 59% response rate in early clinical trials, which has attracted substantial investor interest. Additionally, Grail's Galleri cancer blood test is progressing towards FDA review with enhanced performance data, potentially revolutionizing cancer screening and early detection practices.These scientific and regulatory milestones are complemented by strategic investments in bioconjugation technologies. Cohance Life Sciences' $10 million investment in NJ Bio to enhance GMP bioconjugation capabilities exemplifies this trend. Such investments are crucial for advancing ADC development, which remains a focal point for innovative cancer therapies.Overall, these developments reflect a dynamic phase for the pharmaceutical and biotech sectors characterized by signSupport the show

In this episode of the Evolving Wellness Podcast, host Sarah Kleiner speaks with Dr. Ana-Maria Temple about her integrative approach to chronic childhood conditions like eczema, asthma, and allergies. They explore the limits of conventional treatments such as Dupixent, discuss the role of nutrition, environment, and stress, and highlight alternative solutions like Low Dose Allergen Therapy (LDA). Sarah shares her son's eczema journey and how Dr. Temple's holistic methods helped transform his health. The episode focuses on finding root causes, not just treating symptoms — promoting a more natural, individualized path to lifelong wellness.About Dr. Ana-Maria Temple:Dr. Temple is a board-certified pediatrician and holistic eczema specialist dedicated to helping families uncover the real causes of illness. By focusing on education, prevention, and natural lifestyle shifts, she empowers parents to raise strong, healthy kids in today's toxin-filled world — reducing medications, stress, and chronic symptoms through practical, root-cause healing.Book a FREE call with the Eczema Team:https://eczema.dranamaria.com/application-sarahTopics Discussed:→ The risks of long-term eczema and allergy drugs like steroids & Dupixent→ Why treating root causes (nutrition, toxins, stress) works better than suppression→ The link between diet, processed foods, and childhood chronic illness→ The “allergic march” — how eczema can progress into asthma & allergies→ Prenatal and early-life influences: maternal stress, delivery, antibiotics & diet→ How stress in parents and children impacts immune and brain health→ Integrative tools: LDA therapy, homeopathy, supplements & mindful pharma use→ Why cookie-cutter treatments fail & the need for personalized care→ Supporting parents with compassion — “You did your best with what you knew.”Sponsored By:→ Troscriptions | Optimize your health at http://troscriptions.com/SARAHK — use code SARAHK for 10% off.→ Bon Charge | Shop red light therapy & more: https://us.boncharge.com/products/red-light-face-mask?rfsn=8108115.26608d — use SARAHKLEINER for 15% off storewide.Timestamps00:00 Dupixent Concerns01:25 Overcoming Eczema: Sarah's Story02:33 Meet Dr. Ana-Maria Temple04:19 Journey into Integrative Medicine07:02 Nutrition & Lifestyle Breakthroughs09:01 Pediatric Care Challenges11:55 Flaws in Conventional Medicine30:14 Stress & Environment on Health33:18 1998 Canadian Ice Storm Study34:25 Stress During Pregnancy35:24 Impact on Children's Health37:38 Low Dose Allergen Therapy (LDA)38:58 How LDA Works & Benefits42:16 Modern Medicine Challenges59:02 Closing ThoughtsDisclaimer:This video is not medical advice. Always monitor your labs and work with a professional.Free Guides & Product Recommendations:https://www.sarahkleinerwellness.com/all-free-resourcesCourses on Mitochondrial Health (Use code PODCAST for 10% off):https://www.sarahkleinerwellness.com/coursesJoin My Newsletter for Special Offers:https://www.sarahkleinerwellness.com/contactFree Guide – Build Your Perfect Quantum Day:https://www.sarahkleinerwellness.com/opt-in-9d5f6918-77a8-40d7-bedf-93ca2ec8387fFree Product & Discount Guide:https://www.sarahkleinerwellness.com/resource_redirect/downloads/file-uploads/sites/2147573344/themes/2150788813/downloads/eac4820-016-b500-7db-ba106ed8583_2024_SKW_Affiliate_Guide_6_.pdf

Want to heal your child's eczema naturally and avoid the endless cycle of flares? Click here to get started. When nothing worked, not diet changes, not detoxing, not even Dupixent, Alyssa thought her daughter Amelia would never heal. But today, Amelia is eczema-free, off medication, and living like a carefree child again. Welcome to The Eczema Kids Podcast, hosted by eczema expert and mom of four, Andra McHugh. This is episode one of the Eczema Reset Series, where you'll hear powerful real-life stories and proven strategies to help your child finally heal. Your Next Step: Enroll now inside the Eczema Elimination Method. This is how you finally stop the relentless itch, calm the flares, get your nights back, and free your child — and your whole family — from the grip of eczema. Inside, you'll get a proven family food plan that actually heals (without endless restriction), a mapped-out supplement roadmap so you know exactly what to give and when, and personal coaching to walk you through every step. No more guessing. No more doing this alone. **Enrollment is closing soon, and after September 21st the price increases from $997 to $1,497. Join now and take back your child's health, and your family's peace, starting today.

On this week's episode, hosts Paul Matteis, Sam Fazeli, John Maraganore, and Graig Suvannaveijh kick off the discussion with a more positive look at the sector and some of the fundamental factors at play. The group then shares an overview of Sanofi's 10% stock fall on the back of positive Phase 3 eczema data with worries about the Dupixent patent expiry. The discussion then turns to Insmed, a company that has had a monster year with the stock up 100% and a market cap of over $30 billion market. On the data front, the group highlights ApoC3 data from Ionis and Arrowhead at the European Society of Cardiology Congress 2025, which leads into a discussion around ASO versus RNAi. With multiple obesity readouts in recent weeks, the group theorizes on whether obesity is a zero sum game. It's a big year ahead for AD readouts and the hosts summarizes some important catalysts on the horizon. Other discussion topics include the launch of Corsera Health for cardiovascular prevention, Trump's Truth Social post on vaccine data, RFK Jr in front of congress, and public concern around access to vaccines. This episode aired on September 5, 2025.

We love to hear from our listeners. Send us a message. On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks. Deshpande reflects on his previous experience developing and commercializing Dupixent at Sanofi, describes the history and mechanism of Immediate's glucose-insulin-potassium (GIK) candidate, IMT-358, and explains why there is more to intellectual property than just patents. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Audio roundup of selected biopharma industry content from Scrip over the business week ended August 29, 2025. In this episode: Lilly's orforglipron strong in diabetic obesity; Ascletis confident in oral GLP-1 challenger; myostatin drugs progress for obesity; an interview with OneSource's CEO; and an analysis of Dupixent's pipeline-in-a-product success. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-KKZ7ZW3B2VGUBFTSLNCLIHU7QU/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

In this episode of Let's Combinate, Subhi Saadeh sits down with Jim Collins, a leader in drug delivery with over 30 years of experience at Eli Lilly, Sanofi, and now as an advisor and board member. Jim shares the history of combination products before the term even existed, from insulin pens in the 1990s to modern platforms and on-body injectors. We cover IP battles that reshaped the industry, supply chain risks that pharma still underestimates, and why platform strategy is one of the most important decisions a company can make today.Timestamps:00:00 – Introduction & Guest Welcome02:00 – Building Lilly's device organization and launching insulin pens06:00 – Early “wild west” days of drug delivery vs. today's structure07:00 – Intellectual property as a competitive weapon10:30 – How Lilly, Novo, and Sanofi shaped the IP landscape13:00 – Device differentiation in the generic space17:00 – Portfolio vs. molecule decisions in platform strategy20:00 – Three reasons to develop your own platform23:00 – Supply chain risk and geopolitical considerations26:00 – Black Swan risks and lessons for pharma companies28:00 – Strategic suppliers vs. transactional vendors33:00 – Drug-device integration inside companies37:00 – Building organizational capability and governance38:00 – Future trends: large volume autoinjectors and connected devices43:00 – Impact of tariffs and supply chain positioning45:00 – Where to find Jim CollinsGuest Bio:Jim Collins is a veteran of the drug delivery field with more than 30 years of leadership experience. At Eli Lilly, he built and led the device organization, overseeing the launch of insulin pens, the Forteo Pen, and the Trulicity platform. Later, at Sanofi, he led drug delivery innovation and platform development, including devices for Dupixent. Today, Jim serves as a board member for Enable Injections and advises startups, helping the next generation of innovators navigate IP, supply chain, and platform strategy.Subhi Bio:Subhi Saadeh is a Quality Professional and host of Let's Combinate. With a background in Quality, Manufacturing Operations, and R&D, he has worked in large medical device and pharma organizations to support the development and launch of hardware devices, disposable devices, and combination products for vaccines, generics, and biologics. Subhi serves as International Committee Chair for the Combination Products Coalition (CPC), as a member of ASTM Committee E55, and previously on AAMI's Combination Products Committee. For questions, inquiries, or suggestions, visit letscombinate.com or connect on LinkedIn.

Get ready for a tail-wagging adventure! Oliver Super Beardie, our fearless furry hero and member of the Woof Chat Kids, is back on the case—this time to solve a mysterious throat trouble affecting his buddy Sam. Why is swallowing so hard? What's causing the pain? Oliver's on the trail… and he's sniffing out answers!. Joining Oliver is brilliant expert guest Dr. Sophia Patel, a leading Pediatric Gastroenterologist from Cleveland Clinic. Together with host Jacqueline Gaulin, they'll follow the clues to uncover what's really going on inside Sam's esophagus—and introduce kids (and grown-ups!) to a condition called Eosinophilic Esophagitis (EoE). You'll learn what symptoms to watch for, how EoE is diagnosed, and what steps can help kids like Sam feel better—all in a fun, kid-friendly way that mixes science and heart. A huge shout-out to the incredible John Kennedy, the puppeteer and voice behind Oliver Super Beardie, whose creativity and heart make every episode unforgettable. This special episode is brought to you by Dupixent.  

In this episode, Andrew F. Alexis, MD, MPH; Daniel C. Butler, MD; and Shawn G. Kwatra, MD, discuss IL-13 inhibition for treating patients with moderate to severe atopic dermatitis (AD), including:The available biologic therapies that specifically target IL-13Where these agents fall in the 2024 American Academy of Dermatology treatment algorithmHow these agents compare to other AD therapies like topical corticosteroids and oral JAK inhibitorsA detailed patient case to highlight take home pointsPresenterAndrew F. Alexis, MD, MPH​Professor of Clinical Dermatology​Weill Cornell Medical College ​New York, New YorkDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaShawn G. Kwatra, MD​Dr. Joseph W. Burnett Endowed Professor and Chair ​Department of Dermatology​University of Maryland School of Medicine​Baltimore, MarylandProgram page:https://bit.ly/4kTP04D

In this episode, Daniel C. Butler, MD, and Shawn G. Kwatra, MD, discuss the practical considerations for using IL-13 inhibitors to treat patients with moderate to severe atopic dermatitis, including:Patient candidacy considerationsTreatment advancement strategies that go beyond topical therapiesThe importance of patient-centered care that address patients' fears and needsA detailed patient case to highlight take home pointsPresenterDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaShawn G. Kwatra, MD​Dr. Joseph W. Burnett Endowed Professor and Chair ​Department of Dermatology​University of Maryland School of Medicine​Baltimore, MarylandProgram page:https://bit.ly/4kTP04D

In this episode, Andrew F. Alexis, MD, MPH, and Daniel C. Butler, MD, discuss the immunopathogenesis and role of IL-13 in atopic dermatitis (AD), including:Contributors to epidermal barrier dysfunction (eg, environmental triggers)IL-13 as a key cytokine in AD pathogenesisTargeted AD therapies that inhibit IL-13A detailed patient case to highlight take-home pointsPresenterAndrew F. Alexis, MD, MPH​Professor of Clinical Dermatology​Weill Cornell Medical College ​New York, New YorkDaniel C. Butler, MD​Assistant Dean Student Affairs​University of Arizona College of Medicine – Tucson​Tucson, ArizonaProgram page: https://bit.ly/4kTP04D

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Metsera's new long-acting amylin injection, met-233i, has shown promising weight loss results over eight months, leading to a rise in shares. Meanwhile, CDC vaccine advisors are either being pushed out or leaving their positions. Other top stories include Sirna's expansion beyond the liver, Keros returning $375 million to investors, and ACIP members receiving termination notices. In vitro cell research is focused on slowing aging and preventing age-related diseases. Updates on Merck's oral PCSK9 inhibitor, Sanofi and Regeneron's Dupixent effectiveness, and Avidity's muscular dystrophy drug are also highlighted.The expansion of RNA therapeutics is discussed, with multiple companies aiming to target small interfering RNA to various organs by 2030. Uniqure's regulatory progress in developing a gene therapy for Huntington's disease has sparked optimism, although past disappointments for patients are noted. Perspective Therapeutics presents new data on neuroendocrine tumor treatment at ASCO25. Concerns about RFK Jr.'s vaccine campaign and its potential to increase distrust in vaccines are raised in the editorial. Cancer news, cell and gene therapy updates, upcoming events, job listings, and a call for reader suggestions on coverage topics are also covered.

Audio roundup of selected biopharma industry content from Scrip over the business week ended 6 June 2025. In this episode: Sanofi's Blueprint buy; AstraZeneca's breast cancer resistance results at ASCO; BMS and BioNTech's big bispecific deal; Kymera's Dupixent in a pill; and Degron's CEO on pipeline and strategy. https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-T5ID4HF465BXFGAH7C6OOSEGTA/ This episode was produced with the help of AI text-to-voice and voice emulation tools. Playlist: soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Download the transcript here

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Listen to the podcast here

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. In a recent interview with former Fox News journalist Megyn Kelly, FDA Commissioner Marty Makary discussed a potential new mechanism-driven pathway for expedited rare disease approvals, as well as the possibility of certain environmental factors contributing to autism. Despite Makary's announcement of a directive to limit industry participation in the FDA's advisory committees, industry involvement is actually required by a 1997 law, and banning industry representatives would not have a significant impact. Additionally, the FDA recently approved Sanofi/Regeneron's Dupixent for chronic hives after initially rejecting it, and Lilly has promised to manufacture a weight-loss pill in the US following a Phase III win. The newsletter also includes other news stories, opinions, and upcoming events in the biopharmaceutical industry.

Eczema is also known as a form of Atopic Dermatitis (AD). Males and females are not equally affected by AD, and studies have shown that AD is more common among males during infancy and childhood. However, around puberty, there is a shift towards more females than males having AD and this female predominance continues into adulthood. Eczema can impact any women during pregnancy. In fact, it is the most common prenatal skin condition. A majority of women with eczema in pregnancy have never it previously diagnosed. Actually, approximately 60%–80% of prenatal eczema patients have no prior history of the condition. Eczema in pregnancy may occur because of changes in hormones and the immune system. During pregnancy, the body's immunity shifts a bit and this shift in immunity can make the mother more sensitive to allergens and dermal manifestations vis inflammatory mediators. Those with preexisting common hay fever or other allergies before pregnancy may be at higher risk of developing eczema during pregnancy. Eczema isn't just about “itchy skin”, for some it has severe skin manifestations and affects quality of life. While biologics are generally not initiated in pregnancy except for very severe cases, some women may be on this medication when ENTERING pregnancy. Are they safe to use? We have new SURPRISING data from September 2024 which will help us in our shared-decision making with our patients. Listen in for details.

Is joining a club the key to healing our fractured nation? Would a robot be better than Katie Nolan at bartending? Would you cover your face in fish sperm for dermatological reasons? PLUS: the worst drink to order from a bartender, Dr. Dupixent, frankincense, myrrh, and late-breaking country music news. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Is joining a club the key to healing our fractured nation? Would a robot be better than Katie Nolan at bartending? Would you cover your face in fish sperm for dermatological reasons? PLUS: the worst drink to order from a bartender, Dr. Dupixent, frankincense, myrrh, and late-breaking country music news. Hosted on Acast. See acast.com/privacy for more information.

Is joining a club the key to healing our fractured nation? Would a robot be better than Katie Nolan at bartending? Would you cover your face in fish sperm for dermatological reasons? PLUS: the worst drink to order from a bartender, Dr. Dupixent, frankincense, myrrh, and late-breaking country music news. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Meta-analysis shows NO excessive bleeding problems with Omega-3s; Fish oil found safe for surgery; Dupixent for nasal polyps? Remedies for SIBO (small intestine bacterial overgrowth) in a type 1 diabetic; Less than 5% of the world's population reside in the U.S.—but we consume 65% of the medications! Dr. Oz heart device under scrutiny; Oregon court reverses liability shield for Bayer in Round-Up class action; Movie Review—“Pain Hustlers”, a fictionalized recreation of a real-life opioid medication scandal.